Biotechnology company Thalia Therapeutics has acquired Sanmirna Therapeutics and its clinical-stage cancer RNA therapy. The acquisition catapults Thalia to a clinical-stage RNA therapeutics company, leveraging Sanmirna’s anti-microRNA-126 for the treatment of acute myeloid leukaemia. The deal is believed to be worth £16.675 million ($21.984 million), encompassing an initial… Read More
Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies. Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology… Read More
Nura Bio has completed a $73.8 million Series B financing round as it advances its pipeline of SARM1 inhibitors. The financing, led by The Column Group, is set to fund the development of Nura Bio’s clinical pipeline, including the Phase Ib/IIa study of NB-4746, an oral, brain-penetrant SARM1… Read More
TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million. TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these… Read More
Cellares has raised $327 million for its cell therapy infrastructure project. Cellares, which says it is the first Integrated Development and Manufacturing Organization (IDMO), extended its Series D funding thanks to an additional $50 million investment from Prime Radiant Partners. The investment is set to support the next… Read More
A new agreement is set to advance a vaccine for ovarian cancer which has shown 40% cancer-free survival rates. Biotechnology company CellxLife has entered an agreement with Mayo Clinic for the dendritic cell vaccine, which reported the 40% 10-year cancer-free survival rate in a Phase I Mayo Clinic study… Read More
GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion. The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell… Read More
Bead BioPharma has emerged from stealth by submitting a patent for a novel cancer drug platform. The life sciences company, backed by Archangels, submitted the patent in efforts to launch its formal entry into one of the most competitive sectors of global oncology. Bead BioPharma is focused on antibody-drug conjugates (ADCs), a… Read More
IMU Biosciences has raised $53 million in a Series A financing round, pledging to use the funds to change understanding, diagnosis and treatment of disease. The biotechnology company has built what it claims to be the world’s largest immune dataset, scaling to more than 25,000 individuals in 2026… Read More
Ona Therapeutics has announced it has raised $86.6 million to advance its first-in-class antibody-drug conjugates (ADCs) into clinical development. The biopharmaceutical company raised the money in a Series B financing round, co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys. … Read More
Apogee Therapeutics has entered into a strategic financing collaboration with funds managed by Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive total capital to support the continued development and potential commercialisation of zumilokibart. Combined with company’s current total cash of $1.3 billion, the company… Read More
Pfizer and Innovent Biologics have entered into a collaboration agreement for the research and development of 12 new early-stage cancer medicines, worth up to $10.5 billion. The companies say the partnership includes licensing, co-development, and co-commercialisation opportunities across a portfolio of antibody-drug conjugates (ADCs) with differentiated payloads… Read More
Lilly has reached an acquisition agreement with LimmaTech Biologics AG, a Swiss clinical-stage biotech company, for up to $780 million. The buy-out was part of a spending spree by Lilly on company pipelines that address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens… Read More
Hansa Biopharma and SERB have entered a licensing agreement worth €115 million for the development and commercialisation of a treatment for kidney transplant patients. Idefirix (imlifidase) is a first-in-class treatment that targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six… Read More
Biotechnology company Mediar Therapeutics has enlisted the support of CRO Qureight in the Phase II trial of a treatment for systemic sclerosis. Qureight’s AI 3D quantitative imaging analytics platform and services will be used to support Mediar’s Phase II EncompaSSc clinical trial. The trial will evaluate MTX-474, a monoclonal antibody therapeutic for people with diffuse cutaneous systemic… Read More
UK life sciences company Isomorphic Labs has announced it has raised $2.1 billion to scale its AI drug design engine. The company raised the capital in a Series B financing round, which Isomorphic Labs says will accelerate the company’s evolution from pioneering novel AI models to applying them… Read More
